Displaying drugs 6876 - 6900 of 8198 in total
Lobaplatin
Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, and Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma.
Investigational
Matched Description: … Lobaplatin has been used in trials studying the treatment of Breast Cancer, Hepatocellular Carcinoma, …
Poly(lactic acid)
Poly(lactic acid) is under investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy).
Investigational
Matched Description: … investigation in clinical trial NCT00126308 (Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of …
Istiratumab
Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Investigational
Matched Description: … Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel …
Cerdulatinib
Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).
Investigational
Matched Description: … Cerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib …
NCX-1000
NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of NCX-1000 After Repeated Oral Doses in Patients With Elevated Portal Pressure).
Investigational
Matched Description: … NCX-1000 is under investigation in clinical trial NCT00414869 (Preliminary Efficacy and Tolerability of …
Indatuximab ravtansine
Indatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of …
Pegylated Recombinant Human Arginase I
Pegylated Recombinant Human Arginase I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)).
Investigational
Matched Description: … I is under investigation in clinical trial NCT03455140 (A Study Evaluating the Safety and Activity of …
Quavonlimab
Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
Investigational
Matched Description: … Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination …
SAR421869
SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
Investigational
Matched Description: … a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of …
Vobramitamab duocarmazine
Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors).
Investigational
Matched Description: … Vobramitamab duocarmazine is under investigation in clinical trial NCT05551117 (A Study of Vobramitamab …
4-Hydroxytestosterone
4-Hydroxytestosterone is testosterone substituted with a hydroxy group on the fourth carbon atom. It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency.
Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one of the many byproducts...
Experimental
Illicit
Matched Description: … of the many byproducts of formestane metabolism. ... Formestane (Lentaron) acts as a prohormone of 4-Hydroxytestosterone, as 4-Hydroxytestosterone is one …
NNZ-2591
NNZ-2591 (cyclo-L-glycyl-L-2-allylproline) is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been chemically modified to increase its half-life, stability, and oral bioavailability. It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of Angelman, Phelan-McDermid, and...
Investigational
Matched Description: … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic ... glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been ... [L11106] It is currently under development by Neuren Pharmaceuticals for the symptomatic treatment of …
Rocatinlimab
Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The drug works by targeting the OX40 receptor, which plays a role in the immune response associated with atopic dermatitis. Despite...
Investigational
Matched Description: … Despite its promising results, the long-term safety of rocatinlimab requires further investigation, as ... Rocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe ... Additionally, the diverse genetic backgrounds of patients may influence the drug’s effectiveness and …
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
Matched Description: … OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial ... In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Description: … novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional …
Amperozide
Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons. Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia in humans even though the drug was ultimately never clinically adopted for this indication....
Experimental
Matched Description: … It inhibits dopamine release and alters the firing of dopaminergic neurons. ... Investigations regarding the use of the agent revolved primarily around its capability for treating schizophrenia …
Batroxobin
Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox moojeni. In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate. Batroxobin is a serine protease, which cleaves the 16 Arginine - 17 Glycine bond in fibrinogen. The...
Experimental
Matched Description: … In addition to batroxobin, the venom of Bothrops atrox has a composition of 10.2% neutral carbohydrate ... The MW of batroxobin is approximately 43,000 g/mol-1, and it contains 231 amino acids. ... Batroxobin is a defibrinogenating hemostatic agent derived from the venom of a pit viper, Bothrops atrox …
RH-1
RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma.
Experimental
Investigational
Matched Description: … RH-1 has been used in trials studying the treatment of Advanced Solid Tumors and Non-Hodgkin's Lymphoma …
GlycoPEG-GCSF
GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Investigational
Matched Description: … GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of …
TAK-751S
TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic Escherichia coli.
Investigational
Matched Description: … TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia …
Thiorphan
A potent inhibitor of membrane metalloendopeptidase (enkephalinase). Thiorphan potentiates morphine-induced analgesia and attenuates naloxone-precipitated withdrawal symptoms.
Experimental
Matched Description: … A potent inhibitor of membrane metalloendopeptidase (enkephalinase). …
Dexetimide
A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.
Withdrawn
Matched Description: … Benzetimide is the (-)-enantimorph of dexetimide. …
Rapastinel
Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive Disorder (OCD).
Investigational
Matched Description: … Rapastinel has been used in trials studying the treatment of Depressive Disorder, Major and Obsessive-Compulsive …
VTP-194204
Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung Cancer.
Investigational
Matched Description: … Nrx194204 has been used in trials studying the treatment of Parkinson's Disease and Non-small Cell Lung …
2,4-thiazolidinedione
Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and DIABETES MELLITUS, TYPE 2.
Investigational
Matched Description: … Thiazolidinedione has been investigated for the treatment of Type 2 Diabetes, Diabetes Mellitus, and …
Displaying drugs 6876 - 6900 of 8198 in total